Amur Minerals Corporation

The company did not report revenue or EPS on this presentation. It said it raised GBP 874,000 in June/July and that net cash at the end of September was just over GBP 900,000. For the glioblastoma trial, management said setup costs are about GBP 250,000, roughly GBP 700,000 is needed to reach a reportable data point, and total Part 1 costs are expected to be around GBP 1 million. No forward revenue or earnings guidance was given; instead, the company guided to clinical trial setup, with first patient treatment hoped for early in 2026, and said Part 1 will initially enroll 12 patients, with around 60 patients planned in the broader initial phase.

Andrew Webb emphasized that ChemoSeed is the company’s core asset and said the MHRA approval was a major tipping point because it allows CRISM to move from regulation into trial execution. He highlighted the platform potential beyond brain tumors, pointing to an earlier-started prostate program and the possibility of broader solid-tumor use. His tone was upbeat but practical, repeatedly stressing cash discipline, trial setup, and the need to create value through data.

No formal CFO was present, but Andrew Webb covered financing and capital allocation comments. He said the company raised GBP 874,000 in the June/July fundraise and ended September with just over GBP 900,000 in net cash, while also noting service-contract revenue helps mitigate cash burn. He estimated about GBP 250,000 for trial setup, about GBP 700,000 to reach a reportable data point, and roughly GBP 1 million for total Part 1 costs, while saying the company is likely to partner eventually and must manage runway carefully.

In questions, management was asked how ChemoSeed could develop beyond glioblastoma, and Webb said it could be suitable for most solid tumors, with prostate using docetaxel and pancreatic viewed as more complex because of the 4-drug standard-of-care combination. They were also asked about the cost of treating the first 12 trial patients and how the cash would be raised; management gave the GBP 250,000 setup and about GBP 1 million total Part 1 estimate, saying recruitment speed and multiple clinical sites would matter. On whether the trial could materially improve outcomes, Cruickshank said he could not guarantee it but believed early, local treatment had a good chance of showing benefit, while acknowledging it would be a tall order to move 5-year survival from 5% to 25%.